Myocardial contrast echocardiography assessment of perfusion abnormalities in hypertrophic cardiomyopathy.

"Declarations Ethics approval and consent to participateThe study was approved by the Investigational Review Board at Oregon Health & Science University (IRB 00015158). All subjects gave written informed consent to participate. Consent for publicationNot applicable. Competing interestsMaterial support was provided by Bracco Pharmaceuticals, Princeton, NJ (Lumason ultrasound contrast agent) and by Astellas Pharma, Tokyo, Japan (Lexiscan [regadenoson]). No other financial or non-financial competing interests exist for any of the authors. Competing interests Material support was provided by Bracco Pharmaceuticals, Princeton, NJ (Lumason ultrasound contrast agent) and by Astellas Pharma, Tokyo, Japan (Lexiscan [regadenoson]). No other financial or non-financial competing interests exist for any of the authors."

"Funding Dr. Lindner is supported by grants R01-HL078610, R01-HL130046, and P51-OD011092 from the National Institutes of Health (NIH); and by grant 18-18HCFBP_2-0009 from NASA. Material support was provided by Bracco Pharmaceuticals, Princeton, NJ (Lumason ultrasound contrast agent) and by Astellas Pharma, Tokyo, Japan (Lexiscan [regadenoson]). "

"Trial registration ClinicalTrials.gov NCT02560467."